Sonio

Sonio develops AI-powered software for prenatal diagnosis via fetal ultrasound, offering critical support to healthcare practitioners. The platform precisely analyzes and detects congenital malformations, boosting diagnostic accuracy and efficiency in obstetrical workflows. It provides a modern, integrated solution, enhancing clinical reassurance for medical professionals.

Established in 2020, Sonio was conceived by a team led by CEO Cécile Brosset. The company arose from recognizing that maternal and fetal health imaging lacked advanced AI, leading to diagnostic challenges and outdated systems. This insight fueled Sonio's mission to innovate and elevate prenatal care.

Serving OB-GYN practitioners and clinics, Sonio’s technology enables thorough and reliable prenatal assessments. Its vision is to continuously advance medical AI, fundamentally improving maternal and fetal health outcomes globally. Sonio commits to delivering high-quality prenatal diagnosis, equipping providers with essential tools for mothers' and infants' well-being.

High-Level Overview

Sonio is a healthtech company founded in 2020 that develops AI-powered software for prenatal ultrasound exams, empowering sonographers and clinicians to deliver high-quality maternal and fetal care globally.[2][4][5] Its core products, like Sonio Detect (an FDA-cleared AI assistant for real-time image quality enhancement and anomaly detection) and ultrasound reporting tools, address diagnostic errors in prenatal screening—where birth defects go undetected in up to 50% of cases—serving obstetrics, gynecology, and maternal-fetal medicine professionals in hospitals, clinics, and underserved areas.[4][5][6] Acquired by Samsung Medison in September 2024, Sonio operates independently from Paris, maintaining compatibility with all ultrasound devices while accelerating growth through partnerships; it has raised over €28M in funding and expanded commercially in the US and EU.[4][5][6]

The company serves healthcare providers, IT teams, and clinical executives by streamlining workflows, improving accuracy, and enabling collaboration via tools like Sonio Share and Soniopedia (an educational knowledge base).[6][7] Growth momentum includes FDA and CE clearances for Sonio Detect V2 in 2024, launches at major conferences (SMFM, AIUM, ISUOG), and first US customers like Pediatrix Medical Group, positioning it as a leader in AI-enhanced prenatal care.[5][6]

Origin Story

Sonio emerged from five years of collaboration between world-renowned experts in maternal-fetal medicine at Necker Hospital and data scientists at Ecole Polytechnique, addressing gaps in prenatal ultrasound accuracy.[3][4] Officially founded in April 2020 amid the COVID-19 pandemic, it opened its first Paris office in May 2020; co-founder and CEO Cécile Brosset joined early, leveraging her background in venture capital, healthtech scaling at Bpifrance, and innovation hubs to build the team.[3][5][7]

Pivotal moments include €5M raised in June 2022, a US office in September 2022, €10M from EIC Accelerator in January 2023, €13M Series A in July 2023 alongside FDA clearance for Sonio Detect, and Samsung's acquisition in September 2024—fueling global expansion while preserving independence.[4][5] Early traction stemmed from patented AI algorithms and a proprietary expert database, born from the founders' drive to empower clinicians with technology for better pregnancy outcomes.[2][3]

Core Differentiators

• AI-Powered Precision: Sonio Detect uses deep learning for real-time image optimization, anomaly detection, and complete exam documentation, reducing errors and ensuring highest-quality standards—FDA 510(k) and CE-marked, compatible with any ultrasound system.[4][6]
• Workflow Efficiency: Structured reporting, automation, and tools like Sonio Share enable seamless clinician collaboration and patient pathway optimization, minimizing burnout while upskilling teams.[6][7][8]
• Medical and Data Expertise: Combines clinical input from maternal-fetal specialists with collective intelligence databases and Soniopedia for education, research data sharing, and global accessibility.[2][5][6]
• Scalable Deployment: Flexible, real-time architecture suits any scale, with 24/7 support; post-acquisition, Samsung integration boosts innovation without vendor lock-in.[4][7]

Role in the Broader Tech Landscape

Sonio rides the AI-in-healthcare wave, specifically transforming prenatal sonography amid rising demand for precise, accessible maternal care—exacerbated by workforce shortages, clinician burnout, and global disparities in ultrasound quality.[5][6][8] Timing aligns with regulatory progress (FDA/EU clearances) and market forces like aging populations, increasing birth defect awareness (1 in 33 US/EU babies affected), and AI adoption in medtech, amplified by Samsung's ultrasound dominance.[4][6]

It influences the ecosystem by democratizing high-quality care via vendor-agnostic tools, fostering research through anonymized data, and setting standards at events like SMFM and ISUOG—paving for AI-automated diagnostics and collaborative platforms that extend to underserved regions.[5][6][8]

Quick Take & Future Outlook

Sonio's Samsung backing positions it for explosive growth: expect deeper AI integrations (e.g., advanced anomaly detection, global reporting expansions) and penetration in US/EU markets, with Sonio Detect V2 and Soniopedia driving adoption.[4][6] Trends like AI workforce augmentation, tele-ultrasound, and personalized prenatal pathways will shape its path, potentially revolutionizing outcomes in women's health.[8]

As the "caring company," Sonio evolves from startup innovator to medtech powerhouse, tying back to its mission: uniting tech and expertise for error-free, equitable prenatal care worldwide—watch for breakthrough workflows that redefine global standards.[2][7]